Antibody–drug conjugate development in lymphoma: a systematic clinical trial landscape analysis
IntroductionAntibody–drug conjugates (ADCs) have established roles in selected lymphoma settings, but the maturity, subtype distribution, and platform diversity of the clinical pipeline remain unclear. We mapped interventional trials to evaluate develo…